Image Credit: Adobe Stock Images/JozefMicic.com

Esteve has purchased Regis Technologies, a Chicago-based contract development and manufacturing organization (CDMO), for an undisclosed amount.¹

The deal provides Esteve CDMO—a Spain-based, third-party CDMO that operates under the Esteve Química brand—the opportunity to have a physical presence in the United States, a country where the company has been looking to grow its CDMO services solutions for small-molecule active pharmaceutical ingredients (APIs) the span the entire drug development lifecycle from pre-clinical to commercial manufacturing.

Esteve CDMO specializes in producing high-quality small-molecule active pharmaceutical ingredients (APIs) and intermediates, offering advanced capabilities, including spray drying and high-potency API (HPAPI) manufacturing.

Regis Technologies brings decades of experience in api manufacturing and analytical services

As for Regis Technologies, its history dates back over 65 years. The CDMO provides a multitude of services, ranging from process research & development, current good manufacturing practice (cGMP) API manufacturing, CMC support, and analytical & stability, along with chromatography products.

"We are proud to strengthen our CDMO solutions for pharmaceutical innovators through this acquisition, while welcoming around 70 skilled professionals to our US team," said Joan Petit, Esteve’s chief industrial operations officer and general manager of Esteve CDMO (Esteve Química).

Andrea Oro, the company’s global head of commercial operations and strategy, seconded this excitement, noting that, "this acquisition enhances our early-stage development capabilities, and expands our global manufacturing footprint, allowing us to have an integrated service offering to better respond to our customers' needs."

Shared values and strategic synergies highlight the Esteve–Regis deal

Being family-owned implied a certain type of values, ones that are shared by both parties.

"We are happy to join a company that shares our same values, a company that is also family-owned, with more than 90 years of experience, that is committed to people and focused on delivering long-term value to customers", commented Scott Aladeen, Regis Technologies’ president and CEO.

Esteve broadens oncology portfolio with Caprelsa acquisition from Sanofi

In other Esteve news, the company struck a deal with Sanofi to buy the rights Caprelsa (vandetanib) rights in more than 50 countries, a treatment that is used in adults and children over the age of 5 to battle aggressive and symptomatic medullary thyroid cancer.²

Medullary thyroid carcinoma is a form of cancer that starts in the thyroid gland cells that are responsible for generating the hormone calcitonin. The treatment is a protein tyrosine kinaseinhibitor, which works by blocking tyrosine kinase enzymes. This limits blood flow to the cancer cells, helping to slow the tumor’s growth.²

"Medullary thyroid carcinoma is a rare neuroendocrine tumor that can produce calcitonin from parafollicular cells,” explained José María Giménez-Arnau, Esteve’s chief scientific & medical officer. “The primary treatment is surgery. However, treatments like vandetanib can often slow down or even partially reverse the tumour growth. We at Esteve are proud to join the fighting effort of the patients diagnosed with this carcinoma and their healthcare professionals, with the ambition to continue improving patient's health and lives.”

Esteve deepens rare disease focus with endocrinology expansion

Furthermore, in an effort to become a highly specialized company, Esteve purchased a company focused on the rare and ultra-rare disease space, specifically pertaining to endocrinology and onco-endocrinology.² The deal welcomes three new meds to the Esteve portfolio that helps to tackle endogenous Cushing's syndrome and Adrenocortical Carcinoma.

References

1. Esteve CDMO Acquires Regis Technologies, Expanding US Presence and Capabilities. PR Newswire. July 31, 2025. Accessed August 4, 2025. https://www.prnewswire.com/news-releases/esteve-cdmo-acquires-regis-technologies-expanding-us-presence-and-capabilities-302518453.html

2. Esteve to Acquire Medicine to Treat Medullary Thyroid Cancer. PR Newswire. June 30, 2025. Accessed August 4, 2025. https://www.prnewswire.com/news-releases/esteve-to-acquire-medicine-to-treat-medullary-thyroid-cancer-302493684.html